Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Teva Pharmaceutical Indus
(NYSE:TEVA)
Intraday
$13.87
0.06
[0.43%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$13.87
0.06
[0.43%]
Last update: 9:29AM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 9 days from now on Wed May 8th, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Teva Pharmaceutical Indus Stock (NYSE:TEVA)
Teva Pharmaceutical Indus Stock (NYSE: TEVA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 22, 2024
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
Vandana Singh
-
Apr 22, 2024, 2:37PM
'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo Finance
Benzinga Newsdesk
-
Apr 22, 2024, 12:05PM
Friday, April 19, 2024
Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
Benzinga Newsdesk
-
Apr 19, 2024, 6:11AM
Thursday, April 18, 2024
Teva Pharmaceuticals Decided That Canada Will No Longer Be Included As Part Of Teva's North America Segment As Of Jan. 1, 2024
Benzinga Newsdesk
-
Apr 18, 2024, 4:09PM
Tuesday, April 16, 2024
Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara
Benzinga Newsdesk
-
Apr 16, 2024, 5:33PM
Teva's New Real-World Evidence Presented At The 2024 AAN Annual Meeting Confirms Effectiveness And Patient Satisfaction For HD Chorea With The 4-week Titration Kit For AUSTEDO Tablets
Benzinga Newsdesk
-
Apr 16, 2024, 8:18AM
Friday, April 12, 2024
Teva shares are trading lower. Israel-based stocks have been under pressure amid concerns over Israel-Iran tensions.
Benzinga Newsdesk
-
Apr 12, 2024, 3:47PM
Thursday, April 11, 2024
Teva Announces Results From Phase 3 Study Evaluating Efficacy And Safety OF AJOVY; Says All Critical Efficacy Endpoints Met Significance As Set Out Apriori Through Hierarchical Testing
Benzinga Newsdesk
-
Apr 11, 2024, 8:38AM
Monday, April 08, 2024
Reported Saturday, Teva Pharmaceuticals Presented New Pharmacokinetic Modeling Data By Simulates Clinical Profiles Of Schizophrenia Patients Switching To UZEDY® Extended-Release Injectable Suspension At SIRS 2024
Benzinga Newsdesk
-
Apr 8, 2024, 3:14AM
Wednesday, April 03, 2024
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals Alleging Infringement Of US Patent Numbers 9,040,074 And 9,950,069
Benzinga Newsdesk
-
Apr 3, 2024, 8:26AM
Monday, April 01, 2024
Clinical Collaboration Agreement between Teva And Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Rescue Inhaler Respiratory Program; Teva And Abingworth Enter Strategic Development Funding Agreement To Provide Up To $150M To Offset Program Costs And To Accelerate Clinical Research For Teva's TEV-'248 Program
Benzinga Newsdesk
-
Apr 1, 2024, 8:33AM
Wednesday, March 27, 2024
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
Benzinga Insights
-
Mar 27, 2024, 3:30PM
Tuesday, March 26, 2024
'Supreme Court Unlikely To Limit Access To Abortion Pill' - Washington Post
Benzinga Newsdesk
-
Mar 26, 2024, 12:01PM
Monday, March 25, 2024
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Avi Kapoor
-
Mar 25, 2024, 9:05AM
Friday, March 22, 2024
FTC Files Amicus Brief in Asthma Inhaler Patent Dispute Involving Teva, Amneal; Commission Seeks to Address Teva's Patent Abuse to Promote Affordable Drugs, Generic Competition
Benzinga Newsdesk
-
Mar 22, 2024, 1:56PM
Thursday, March 21, 2024
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Vandana Singh
-
Mar 21, 2024, 7:17AM
Friday, March 08, 2024
8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Benzinga Insights
-
Mar 8, 2024, 9:00AM
JP Morgan Upgrades Teva Pharmaceutical Indus to Neutral, Announces $14 Price Target
Benzinga Newsdesk
-
Mar 8, 2024, 8:12AM
Monday, March 04, 2024
'France becomes first country to explicitly enshrine abortion rights in constitution' -Washington Post Report
Benzinga Newsdesk
-
Mar 4, 2024, 12:53PM
Monday, February 26, 2024
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Feb 26, 2024, 1:57PM
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Feb 26, 2024, 12:35PM
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
Vandana Singh
-
Feb 26, 2024, 8:48AM
Teva shares are trading higher after the company announced FDA approval of its arthritis treatment.
Luke J Jacobi
-
Feb 26, 2024, 8:22AM
Late Friday, Alvotech And Teva Pharmaceutical Industries Announced That FDA Approved Simlandi (Adalimumab-ryvk) Injection, As An Interchangeable Biosimilar To AbbVie's Arthritis Drug Humira
Benzinga Newsdesk
-
Feb 26, 2024, 7:22AM
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine) For Neurodegenerative And Movement Disorders
Benzinga Newsdesk
-
Feb 26, 2024, 7:08AM
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Avi Kapoor
-
Feb 26, 2024, 7:03AM
Tuesday, February 20, 2024
Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report
Vandana Singh
-
Feb 20, 2024, 1:24PM
Teva Presents New Data Supporting Safety, Tolerability And Target Engagement Of Anti-TL1A Antibody At The 2024 ECCO Annual Meeting
Benzinga Newsdesk
-
Feb 20, 2024, 8:55AM
Monday, February 12, 2024
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Priya Nigam
-
Feb 12, 2024, 11:53AM
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
Avi Kapoor
-
Feb 12, 2024, 10:22AM
Teva Pharmaceuticals shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $12 to $19.
Benzinga Newsdesk
-
Feb 12, 2024, 8:49AM
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
-
Feb 12, 2024, 7:43AM
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock
Benzinga Insights
-
Feb 12, 2024, 7:00AM
Piper Sandler Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $19
Benzinga Newsdesk
-
Feb 12, 2024, 5:29AM
Monday, February 05, 2024
Goldman Sachs Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $11
Benzinga Newsdesk
-
Feb 5, 2024, 10:52AM
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $17
Benzinga Newsdesk
-
Feb 5, 2024, 8:53AM
Wednesday, January 31, 2024
Teva Pharmaceutical Industries CEO Francis Says Still Expects U.S Humira Near Copy Launch, Despite AbbVie Holding Around 99% Of Market In 2023
Benzinga Newsdesk
-
Jan 31, 2024, 12:21PM
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Jan 31, 2024, 11:02AM
Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates
Vandana Singh
-
Jan 31, 2024, 10:14AM
Teva Pharmaceuticals shares are trading lower after the company reported Q4 results and issued guidance.
Benzinga Newsdesk
-
Jan 31, 2024, 8:53AM
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
Shanthi Rexaline
-
Jan 31, 2024, 7:46AM
Teva Pharmaceutical Industries Sees 2024 Revenues Of $15.7B-$16.3B, With Adjusted EPS Of $2.20-$2.50 Versus Consensus Of $15.56B And $2.42, Respectively
Benzinga Newsdesk
-
Jan 31, 2024, 7:05AM
Teva Pharmaceutical Q4 Adjusted EPS $1.00 Beats $0.76 Estimate, Sales $4.46B Beat $3.99B Estimate
Benzinga Newsdesk
-
Jan 31, 2024, 7:03AM
Earnings Scheduled For January 31, 2024
Benzinga Insights
-
Jan 31, 2024, 6:09AM
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
Benzinga Newsdesk
-
Jan 31, 2024, 6:04AM
Tuesday, January 30, 2024
A Preview Of Teva Pharmaceutical Indus's Earnings
Benzinga Insights
-
Jan 30, 2024, 9:01AM
Monday, January 29, 2024
Check Out What Whales Are Doing With TEVA
Benzinga Insights
-
Jan 29, 2024, 3:00PM
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $15
Benzinga Newsdesk
-
Jan 29, 2024, 7:05AM
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
Shanthi Rexaline
-
Jan 29, 2024, 5:51AM
Tuesday, January 23, 2024
Teva shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $10 to $14.
Benzinga Newsdesk
-
Jan 23, 2024, 1:24PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch